◼ ACE1702 is the first antibody-conjugated NK cell therapy in clinical development for the treatment of HER2-expressing solid tumors
◼ Clinical trial expected to enroll up to 24 patients across the U.S.
◼ ACE1702 is the first antibody-conjugated NK cell therapy in clinical development for the treatment of HER2-expressing solid tumors
◼ Clinical trial expected to enroll up to 24 patients across the U.S.